Clinic Time Required for Remote and In-Person Management of Patients With Cardiac Devices: Time and Motion Workflow Evaluation.

Background: The number of patients with cardiac implantable electronic device (CIED) is increasing, creating a substantial workload for device clinics.

Objective: This study aims to characterize the workflow and quantify clinic staff time requirements for managing patients with CIEDs.

Methods: A time and motion workflow evaluation was performed in 11 US and European CIEDs clinics.

Performance of a new atrial fibrillation detection algorithm in a miniaturized insertable cardiac monitor: Results from the Reveal LINQ Usability Study.

Background: For clinicians, confidence in atrial fibrillation (AF) episode classification is an important consideration when electing to use insertable cardiac monitors (ICMs).

Objective: The purpose of this study was to report on the improved AF detection algorithm in the Reveal LINQ ICM.

Methods: The Reveal LINQ Usability Study is a nonrandomized, prospective, multicenter trial.

Safety Profile of a Miniaturized Insertable Cardiac Monitor: Results from Two Prospective Trials.

Background: Insertable cardiac monitors (ICMs) are used to continuously monitor the patient's electrocardiogram. In response to patient activation or based on automated device algorithms, arrhythmia episodes are stored and automatically transmitted daily to the clinician. Thus, ICMs can be used to diagnose arrhythmias in at-risk patients and in those with symptoms potentially attributable to arrhythmias.

Miniaturized Reveal LINQ insertable cardiac monitoring system: First-in-human experience.

Background: The Reveal LINQ is a miniaturized insertable cardiac monitor (ICM) with wireless telemetry for remote monitoring of patients with suspected arrhythmias.

Objective: The primary objective of this study was to evaluate the functionality of the Reveal LINQ system by measuring R-wave sensing and data transmission.

Methods: The Reveal LINQ Usability Study was a nonrandomized, prospective, multicenter trial.

An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease.

Aims: Selisistat, a selective SirT1 inhibitor is being developed as a potentially disease-modifying therapeutic for Huntington's disease (HD). This was the first study of selisistat in HD patients and was primarily aimed at development of pharmacodynamic biomarkers.

Methods: This was a randomized, double-blind, placebo-controlled, multicentre exploratory study.